Biomoda, Inc.

Patent Portfolio

 Print Version

The following table summarizes the key U.S. Patent estate of Biomoda.  Patent protection in numerous foreign countries, based on these domestic patents, is in place or pending.

U.S. Patent Title

• 6,838,248 – Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine
• 7,384,764 – Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine
• 7,670,799 – Compositions and Methods of Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine
• 61/226,646-  System and Method for Analyzing Samples Labeled with 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphine(TCPP) (Pending)
• Method for Detecting and Prognosing Pre-Cancerous Cells Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine which relates to the use of certain porphyrins to detect dysplastic, pre-cancerous, and cancerous cells from various tissue samples both in-vitro and in-situ.
• 429,526 – Compositions and Methods for Detecting Precancerous Conditions in Cells and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine.  This patent is similar to the U.S. Patent awarded in 2005.  Biomoda now has foreign patent rights in Australia, Canada, Japan, and Mexico.
• Japan Patent Office granted Patent Application No. 2008-266490 – Compositions and Methods for Detecting Precancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine, which is similar to Biomoda’s U.S. patent 6,838,248.  Foreign equivalents are now effective in Canada, Mexico, and Australia.
• European Patent No. 01987011.2 which is similar to Biomoda’s U.S. patent 6,838,248.
• Pending application for a new U.S. Patent.  It is a Utility Patent describing systems and methods for an innovative stable, narrow-band light source to excite fluorophores such as TCPP.  This narrow-band fluorophore exciter will increase the accuracy, sensitivity, and specificity of the Cypath® diagnostic assay for lung cancer in both epifluorescent microscopy and flow cytometry.
• The U.S. Patent and Trademark Office has registered the marks Cypath® and CyDx®, and the World Intellectual Property Organization has registered Biomoda as a world trademark.